Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seven patients with hyperlipoproteinemia (HLP) type II (four patients with type II A and three patients with type II B), who were experienced to be resistant to hypolipidemic drugs, were treated for 6 months with etofibrate, a double-ester of nicotinic acid and clofibrinic acid, at a dose of 0.3 g t.i.d. Mean serum cholesterol level decreased by up to 18% from a pre-treatment value of 7.7 +/- 1.4 mmol/l. The reduction of serum cholesterol was due both to a decrease in very low density (VLDL) and low density (LDL) lipoprotein cholesteral by 61 and 25%, respectively (after 6 months). Furthermore alpha-LP (HDL) cholesterol increased by 8%, (after 6 months). All seven patients had previously received clofibrate and had obtained a mean decrease in plasma cholesterol by 6%. There was a slight transient increase in S-ASAT and S-ALAT simultaneous with in increase in serum urate. However, these values returned after 3 months to pre-treatment level. No influence on glucose tolerance was recorded. There were no bothersome side effects except a transient discomfort in the form of flushing or acid indigestion which occurred after 1--2 months of treatment with etofibrate.
 ...
PMID:Treatment of hyperlipoproteinemia type II with etofibrate. 52 96

Daily butyric acid doses of 0.5 g/kg body weight or 1.0 g/kg were intraruminally applied to 8 young fattening bulls together with regular feed rations, for 19 days, following an initial phase for adaptation. Indigestion phenomena were recordable from 30% of the animals, primarily on the early days of the experiment. Both doses produced sinusoidal beta-OH butyrate curves without major dose-dependent deviations. The concentrations of glucose and free fatty acids were indicative of temporary subclinical ketosis. Neither ASAT, ALAT, and gamma-glutamyltransferase nor bilirubin nor liver glycogen were indicative of liver damage. The lower dose of 0.5 g/kg was widely tolerated, but clearly discernible disorders developed in response to the higher dose of 1.0 g/kg of butyric acid.
 ...
PMID:[Subacute butyric acid burden in cattle. 1. Clinical results and effects on the carbohydrate-fat metabolism and the liver function of young fattening bulls]. 277 40

This study was carried out to assess the efficacy, safety and tolerability of fluvastatin as monotherapy in the treatment of primary hypercholesterolemia. This multicenter study started with 467 patients but only 315 subjects completed 12 weeks treatment. Patients followed a standard lipid-lowering diet for 3 weeks before entering and throughout the study. Every patient received fluvastatin 20 mg once daily with the evening meal for the first 6 weeks, from week 7 to week 12 the daily dose was changed to one capsule 40 mg daily in the evening. Results showed that the mean percent changes in lipid parameters between baseline and endpoint was as follows: LDL-C (-32.7%); total cholesterol (-29.42%), triglycerides (-19.7%) and HDL-C (16.6%). Meanwhile, the mean percent increase in liver enzymes between baseline and endpoint was 17.2% for ASAT and 20.3% for ALAT, respectively, but the mean values of both enzymes at the endpoint were within normal range. The most frequent side effects being gastrointestinal (4.3%) including dyspepsia, nausea, flatulence and diarrhea. In conclusion, fluvastatin as monotherapy in the treatment of hypercholesterolemia among Saudis was found to be safe, well tolerated and produced a significant improvement in the overall lipid parameters.
 ...
PMID:Saudi Arabia experience trial of fluvastatin (Lescol) in the treatment of hyperlipidemia. 1721 90